Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
"its fairly safe to say he is short all those companies he has bashed "
This not my impression at all.
Dr. Schwartz has invested a lot of time and effort researching a vaccine he was hoping to invest in, but because he has a conflict with the PII model he couldnt. The PII tests were designed by Dr. Peoples, an immunologist in the trenches, and not by a biochemist who would have been much more exacting.
My impression is that Dr. Schwartz wrote this paper to recoup some of his investment in researching GALE and was hoping, maybe, to provoke a convincing counterargument that would get him to change his evaluation of the risk.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
What was the name of the scientist who proposed that GM-CSF might cure Crohn's? Anyways, yes, I agree, on the face of it the PIII trial has a higher hurdle for a number of reasons. Not because GM-CSF cures breast cancer, but because with GM-CSF in the control arm there is zero chance of the placebo effect, also it is a double blinded study. On the other hand, not only is the PIII study more selective, more targeted, the pts. are also optimally dosed.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
...and no bone metastasis in the vaccinated group, if I recall from those early studies! Did you catch that? Astounding! But why would you conclude from this that the active group had a lower hurdle?
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
"Galena repeatedly stated that high expressing Her-2 tumors down-regulate HLA expression rendering them invisible to the immune system."
In all the early papers and news reports published by Galena, I never read a pronouncement that NeuVax had absolutely no effect in the +3 patient population. Only that the effect was marginal. The booster program changed the outcome.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Are we talking about the PII trials again? Can you imagine the outcry if the vaccinated group were NN patients and the control group NP patients?????????????
Dr. Peoples modeled the PIIs as if he wanted them to fail. You, as a biochemist, may find this offensive, but this is exactly the approach I would want an immunologist to take.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Dr Schwartz, I know Redplate's agenda, but I don't know yours. I was surprised to read your above slander against the researchers of Galena (Peoples, Mittendorf et al.) . You wrote, "GALE lied about the mechanism-of-action....." I would not expect this lack of equanimity in a scientist of your stature.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
"Just before you give a response please understand that my specialty is immunogenetics and how peptides either do or do not 'fit' with HLA and how those dynamics predict responses. "
Redplate, you are tripping over your agenda for the Tapimmune peptide.
Trials SN-33 (NP) (n=97) and SN-34 (NN) (n=90) enrolled clinically eligible patients who had completed standard of care (n=187). Treatment assignment was then based on HLA type, with HLA A2/A3 patients vaccinated and HLA-A2/A3 negative patients followed prospectively as controls for recurrence.
Sure there is a difference, but it skews against NeuVax. The NN control arm has a less probablility of recurrence.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
"The largest 'problem' with the early studies was using genetically distinct pts as a 'control arm'. "
Sheesh, get a room you two. Robert, let me introduce you to Redplate, who like you, is a distinguished biochemist.
Redplate, you never cease to blow smoke about NeuVax. The only difference in the control arm was that the pts were NN as opposed to NP. Statistically, this actually tilts the table against NeuVax!!!!
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
"but rather do 'present' a cross reactive target (AA373-382), and this is a 'modest' (or weak) cross reaction. Knutson Henle were clear on this in J Imm in January."
Tapimmune's peptide is the one infringing on the E75 mechanism. A blatant land grab like Alnylam's bald-faced misappropriation of the MC3 lipid.
Revisiting HFC: Wrong So Far, But... [View article]
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Perhaps now, Dr. Schwartz will see that his orthodoxy might be doing his clients a great disservice.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
This not my impression at all.
Dr. Schwartz has invested a lot of time and effort researching a vaccine he was hoping to invest in, but because he has a conflict with the PII model he couldnt. The PII tests were designed by Dr. Peoples, an immunologist in the trenches, and not by a biochemist who would have been much more exacting.
My impression is that Dr. Schwartz wrote this paper to recoup some of his investment in researching GALE and was hoping, maybe, to provoke a convincing counterargument that would get him to change his evaluation of the risk.
Is this a fair impression?
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
And, I would add, there is almost no statistical difference in recurrence in these two cohorts. Note: I said "recurrence."
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
In all the early papers and news reports published by Galena, I never read a pronouncement that NeuVax had absolutely no effect in the +3 patient population. Only that the effect was marginal. The booster program changed the outcome.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Dr. Peoples modeled the PIIs as if he wanted them to fail. You, as a biochemist, may find this offensive, but this is exactly the approach I would want an immunologist to take.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Less skewed, more balanced of course. GM-CSF is well documented.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Redplate, you are tripping over your agenda for the Tapimmune peptide.
Trials SN-33 (NP) (n=97) and SN-34 (NN) (n=90) enrolled clinically eligible patients who had completed standard of care (n=187). Treatment assignment was then based on HLA type, with HLA A2/A3 patients vaccinated and HLA-A2/A3 negative patients followed prospectively as controls for recurrence.
Sure there is a difference, but it skews against NeuVax. The NN control arm has a less probablility of recurrence.
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Sheesh, get a room you two. Robert, let me introduce you to Redplate, who like you, is a distinguished biochemist.
Redplate, you never cease to blow smoke about NeuVax. The only difference in the control arm was that the pts were NN as opposed to NP. Statistically, this actually tilts the table against NeuVax!!!!
Galena Biopharma's NeuVax Vaccine: What To Know Before You Invest [View article]
Tapimmune's peptide is the one infringing on the E75 mechanism. A blatant land grab like Alnylam's bald-faced misappropriation of the MC3 lipid.
Stock Options Or Pilfered Savings? Maybe This Cyprus Thing Is A Copycat Raid On Wealth [View article]
........lets keep this author on top!!!!